BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
7/12/2021 5:45:28 AM | Browse: 363 | Download: 654
 |
Received |
|
2021-03-13 19:10 |
|
Peer-Review Started |
|
2021-03-13 19:24 |
 |
To Make the First Decision |
|
|
|
Return for Revision |
|
2021-03-30 01:54 |
|
Revised |
|
2021-03-30 10:23 |
|
Second Decision |
|
2021-06-22 09:19 |
|
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Company Editor-in-Chief |
|
2021-06-22 09:59 |
|
Articles in Press |
|
2021-06-22 09:59 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
2021-06-25 23:04 |
|
Typeset the Manuscript |
|
2021-07-08 04:26 |
|
Publish the Manuscript Online |
|
2021-07-12 05:45 |
| ISSN |
1948-9358 (online) |
| Open Access |
This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2021. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Medicine, General & Internal |
| Manuscript Type |
Opinion Review |
| Article Title |
Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jelena Marinkovic-Radosevic, Maja Cigrovski Berkovic, Egon Kruezi, Ines Bilic-Curcic and Anna Mrzljak |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Maja Cigrovski Berkovic, MD, Assistant Professor, Department of Endocrinology, Diabetes, Metabolism and Clinical Pharmacology, Clinical Hospital Dubrava, Ulica Gojka Šuška 6, Zagreb 10000, Croatia. maja.cigrovskiberkovic@gmail.com |
| Key Words |
Polycystic ovary syndrome; Sodium-glucose co-transporter-2 inhibitors; Metabolic risk; Cardiovascular risk; Metabolic syndrome; Insulin resistance; Obesity; Type 2 diabetes mellitus; Dyslipidemia |
| Core Tip |
Sodium-glucose co-transporter-2 (SGLT-2) inhibitors are a new class of antidiabetic agents with beneficial cardiovascular, bodyweight, and antihyperglycemic effects. Although not approved for the treatment of polycystic ovary syndrome (PCOS), they might be an attractive therapeutic addition for the related metabolic, reproductive, and psychological consequences. Recent studies with SGLT-2 inhibitors in PCOS patients showed promising improvements in anthropometric parameters and body composition. Thus, it is important to explore the SGLT-2 inhibitors potential as an early therapeutic option in PCOS due to its high cardiometabolic risk. |
| Publish Date |
2021-07-12 05:45 |
| Citation |
Marinkovic-Radosevic J, Cigrovski Berkovic M, Kruezi E, Bilic-Curcic I, Mrzljak A. Exploring new treatment options for polycystic ovary syndrome: Review of a novel antidiabetic agent SGLT2 inhibitor. World J Diabetes 2021; 12(7): 932-938 |
| URL |
https://www.wjgnet.com/1948-9358/full/v12/i7/932.htm |
| DOI |
https://dx.doi.org/10.4239/wjd.v12.i7.932 |
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
